BioMarin EVP granted RSUs, options and tax share withholding

BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction.

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction. On March 16, 2026, she received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock at an exercise price of $57.43 per share. The option grant vests 12/48ths on March 16, 2027, with the remaining 36/48ths vesting in equal monthly installments of 1/48th on the 16th day of each month thereafter.

On March 17, 2026, 1,245 shares of Common Stock were disposed of at $56.05 per share in a tax-withholding transaction to satisfy tax obligations, rather than an open-market sale. After these transactions, Hubbard directly held 44,790 shares of BioMarin Common Stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Hubbard Cristin

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,245	$56.05	$70K
Grant/Award	Stock Option (Right to Buy Common Stock)	36,680	$0.00	$0.00
Grant/Award	Common Stock	15,410	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy Common Stock) — 36,680 contracts (Direct); Common Stock — 44,790 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units granted March 16, 2026. Price not applicable.
2. F2. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

FAQ

What insider transactions did Cristin Hubbard report for BioMarin (BMRN)?

Cristin Hubbard reported equity compensation grants and a tax-related share disposition. She received restricted stock units and a stock option award, then had a small number of shares withheld the next day to cover tax obligations, rather than executing an open-market stock sale.

How many BioMarin (BMRN) shares and options were granted to Cristin Hubbard?

Hubbard received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock. The option has an exercise price of $57.43 per share and represents a new award of derivative securities.

What is the vesting schedule for Cristin Hubbard’s new BioMarin stock option?

The stock option vests 12/48ths on March 16, 2027, then 1/48th on the 16th day of each following month. This creates a four-year vesting period, with a larger initial vesting installment followed by equal monthly vesting installments thereafter.

What was the purpose of the 1,245 BioMarin (BMRN) shares disposed of by Cristin Hubbard?

The 1,245 shares of Common Stock disposed of on March 17, 2026, were used for tax withholding. This transaction covered tax liabilities by delivering shares, and is classified as a tax-withholding disposition, not an open-market sale of stock.

How many BioMarin (BMRN) shares does Cristin Hubbard hold after these transactions?

Following the reported transactions, Cristin Hubbard directly held 44,790 shares of BioMarin Common Stock. This total reflects her position after receiving restricted stock units and after the tax-withholding disposition of 1,245 shares to satisfy related tax obligations.

Do Cristin Hubbard’s BioMarin Form 4 transactions indicate buying or selling shares?

The filing shows equity awards and tax withholding, not open-market trading. She acquired shares and options as compensation and disposed of 1,245 shares for tax withholding, which is a mechanical step to pay taxes rather than a discretionary sale in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 01:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hubbard Cristin

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		A		15,410	A	$0(1)	46,035	D
Common Stock	03/17/2026		F		1,245	D	$56.05	44,790	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$57.43	03/16/2026		A		36,680		03/16/2027(2)	03/15/2036	Common Stock	36,680	$0	36,680	D

Explanation of Responses:

1. Restricted stock units granted March 16, 2026. Price not applicable.

2. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)